- Home
- NUVB vs ACP Comparison
NUVB vs ACP Comparison
Compare NUVB & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- ACP
- Stock Information
- Founded
- NUVB 2018
- ACP 2010
- Country
- NUVB United States
- ACP United States
- Employees
- NUVB N/A
- ACP N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- ACP Investment Managers
- Sector
- NUVB Health Care
- ACP Finance
- Exchange
- NUVB Nasdaq
- ACP Nasdaq
- Market Cap
- NUVB 837.0M
- ACP 737.8M
- IPO Year
- NUVB N/A
- ACP N/A
- Fundamental
- Price
- NUVB $3.89
- ACP $5.90
- Analyst Decision
- NUVB Strong Buy
- ACP
- Analyst Count
- NUVB 6
- ACP 0
- Target Price
- NUVB $8.00
- ACP N/A
- AVG Volume (30 Days)
- NUVB 6.2M
- ACP 337.9K
- Earning Date
- NUVB 11-05-2025
- ACP 01-01-0001
- Dividend Yield
- NUVB N/A
- ACP 17.79%
- EPS Growth
- NUVB N/A
- ACP N/A
- EPS
- NUVB N/A
- ACP N/A
- Revenue
- NUVB $14,355,000.00
- ACP N/A
- Revenue This Year
- NUVB $332.80
- ACP N/A
- Revenue Next Year
- NUVB $360.12
- ACP N/A
- P/E Ratio
- NUVB N/A
- ACP N/A
- Revenue Growth
- NUVB 900.35
- ACP N/A
- 52 Week Low
- NUVB $1.54
- ACP $5.55
- 52 Week High
- NUVB $4.09
- ACP $7.17
- Technical
- Relative Strength Index (RSI)
- NUVB 83.37
- ACP 44.02
- Support Level
- NUVB $2.87
- ACP $5.94
- Resistance Level
- NUVB $3.08
- ACP $5.94
- Average True Range (ATR)
- NUVB 0.22
- ACP 0.03
- MACD
- NUVB 0.08
- ACP -0.01
- Stochastic Oscillator
- NUVB 86.52
- ACP 20.91
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.